Edition:
United Kingdom

Precision Therapeutics Inc (AIPT.OQ)

AIPT.OQ on NASDAQ Stock Exchange Capital Market

0.91USD
16 Apr 2018
Change (% chg)

-- (--)
Prev Close
$0.91
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
102,914
52-wk High
$2.58
52-wk Low
$0.81

Chart for

About

Precision Therapeutics Inc., formerly Skyline Medical Inc., is a medical device company that develops and manufactures The STREAMWAY System, a solution for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. The Company distributes these products to hospitals, surgical... (more)
No analyst recommendations are available for .

Overall

Beta: 1.17
Market Cap(Mil.): $10.16
Shares Outstanding(Mil.): 6.23
Dividend: --
Yield (%): --

Financials

  AIPT.OQ Industry Sector
P/E (TTM): -- 148.40 32.74
EPS (TTM): -1.10 -- --
ROI: -245.78 9.37 14.38
ROE: -284.90 14.69 16.07

BRIEF-Precision Therapeutics Q4 Loss Per Share $0.43

* PRECISION THERAPEUTICS REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS

02 Apr 2018

BRIEF-Precision Therapeutics Announces Record Streamway System Sales In The First Three Months Of 2018

* PRECISION THERAPEUTICS ANNOUNCES RECORD STREAMWAY® SYSTEM SALES IN THE FIRST THREE MONTHS OF 2018

29 Mar 2018

BRIEF-Precision Therapeutics Unit Announces License Agreement With Cellbridge Inc

* PRECISION THERAPEUTICS SUBSIDIARY, TUMORGENESIS, ANNOUNCES LICENSE AGREEMENT WITH CELLBRIDGE INCORPORATED

21 Mar 2018

BRIEF-Precision Therapeutics Subsidiary, Tumorgenesis, Announces License Agreement With 48Hour Discovery

* PRECISION THERAPEUTICS SUBSIDIARY, TUMORGENESIS, ANNOUNCES LICENSE AGREEMENT WITH 48HOUR DISCOVERY Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

15 Mar 2018

BRIEF-Precision Therapeutics Unit, Tumorgenesis, Announces License Agreement With Syntarray LLC

* PRECISION THERAPEUTICS SUBSIDIARY, TUMORGENESIS, ANNOUNCES LICENSE AGREEMENT WITH SYNTARRAY, LLC

13 Mar 2018

Earnings vs. Estimates

No consensus analysis data available.